Advisory Panel For Bristol's Yervoy Is Called Off, Which May Bode Well
This article was originally published in The Pink Sheet Daily
Executive Summary
After extending the review, FDA says it no longer needs ODAC's advice on the second-line melanoma treatment, which looks like a good sign for approval.